MK7684A-005 - A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid (KEYVIBE-005)

Studio Clinico

Patologia: Carcinoma della vescica, Epatocarcinoma, Neoplasie della mammella, Neoplasie dello stomaco, Tumori dell’esofago, Tumori delle vie biliari, Tumori dell’utero, Tumori dell’ovaio, Tumori della testa e del collo, Altre neoplasie

Osservazionale-Sperimentale: Sperimentale

Monocentrico-Multicentrico: Multicentrico

Randomizzato: No

Fase di studio: II

Linee di trattamento: Non applicabile

Criteri di inclusione: 

• One of the following histologically or cytologically confirmed, advanced (locally recurrent unresectable or metastatic) solid tumors:
  - Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
  - Endometrial cancer
  - Head and neck squamous cell carcinoma (HNSCC)
  - Unresectable biliary adenocarcinoma (gallbladder or biliary tree [intrahepatic or extrahepatic] cholangiocarcinoma)
  - Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ).
  - Triple-negative breast cancer (TNBC)
  - Hepatocellular carcinoma (HCC)
  - Urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra
  - Ovarian cancer
  - Gastric cancer
• Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator.
• Adequately controlled blood pressure (BP) with or without antihypertensive medications.
• Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).
• Male participants must agree to follow contraceptive guidance.
• Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.
• Adequate organ function.

Criteri di esclusione: 

• History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
• Prior therapy with anti-programmed cell-death (PD-1), anti-PD-L1, anti-PD-L2, or anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) agent.
• Prior systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation.
• Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
• Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study medication.
• Active autoimmune disease that has required systemic treatment in past 2 years.
• Active infection requiring systemic therapy.
• Concurrent active hepatitis B and hepatitis C virus infection.
• History of allogenic tissue/solid organ transplant.
• Previous treatment with lenvatinib (for participants who will receive lenvatinib in their assigned treatment arm).
• Has clinically significant cardiovascular disease within 12 months from first dose of study intervention.

Trattamento sperimentale: 

pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies

Trattamento di controllo: 

NA

Centri partecipanti

Nord Italia

Centro Italia

Sud Italia e isole

Informazioni Generali

Protocollo

Numero di iscrizione a registro: NCT05007106

Data di inserimento: 11.05.2022

Data di aggiornamento: 23.11.2023

Promotore

Merck Sharp & Dohme LLC

CRO

/

Principal Investigator ITALIA

Istituto Nazionale Tumori IRCCS Fondazione Pascale

Riferimento: Dr. Adriano Gravina

Telefono: 0815903448

Email: a.gravina@istitutotumori.na.it

Localita: Napoli